Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
Clinical trial NCT02444819 · COMPLETED
Trial details
- NCT number
- NCT02444819
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2017-08-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.